EMA: No evidence to support restricting Oxford jab
There is “no evidence” to support restricting the use of the Oxford/AstraZenecaCovid-19 vaccine in any population, European Medicines Agency (EMA) executive director Emer Cooke has said.
A new intranasal vaccine developed by researchers at the Wuhan lab has recently been unveiled, promising a novel approach to combating infectious diseases. However, this breakthrough has also sparked significant controversy and concern. While the vaccine’s potential to offer a more accessible and efficient method of vaccination is hailed as a major advancement, its origins and the circumstances surrounding its development are raising alarms about a possible new health crisis. Critics worry that the technology used in this vaccine could inadvertently lead to another pandemic-like scenario if not carefully monitored. As the world cautiously watches, the vaccine's rollout is stirring a heated debate about safety, preparedness, and the ethical implications of such advanced biological research.
#IntranasalVaccine #WuhanLab #CovidCrisis #HealthFears #VaccineDebate #PandemicRisk #BioResearch #VaccineDevelopment #PublicHealth #InfectiousDiseases #SafetyConcerns #GlobalHealth #VaccineInnovation #EthicalIssues #HealthSecurity
~HT.97~PR.152~
![Cure or Threat? Wuhan Lab's New Intranasal Vaccine Sparks Fears of Another Covid-like Crisis [Video]](https://video.newsserve.net/300/v/20240912/1387343466-Cure-or-Threat-Wuhan-Lab-New-Intranasal.jpg)
